MedReleaf Report issue

For profit Phase 3
Founded: Markham ON Canada (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2018
NCT03522467
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

MedReleaf

Active Ingredients

Drugs in Phase 3 Trials (1)

cannabis (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 2)

Drug Resistant Epilepsy (Phase 3)

Epilepsy (Phase 3)

Marijuana Abuse (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1